The use of Nutlin-3A, an inhibitor of MDM2 to treat MAPK inhibitor-resistant melanoma cells results in a dose-dependent manner to restore FBXW7 expression and p63 degradation and increase the sensitivity of these cancer cells to apoptosis, thus Nutlin-3A as a way to eliminate melanoma resistance to MAPK inhibitors is worthy of further study (117). Here, MDM2 is linked to melanoma.